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ABSTRACT  55 
Multidrug-resistant Enterobacteriaceae (MRE) colonize the intestine asymptomatically 56 
from where they can breach into the bloodstream and cause life-threatening infections, 57 
especially in heavily colonized patients. Despite the clinical relevance of MRE colonization 58 
levels, we know little about how they vary in hospitalized patients and the clinical factors 59 
that determine those levels. Here we conducted one of the largest studies of MRE fecal 60 
levels by tracking longitudinally 133 acute leukemia patients and monitoring their MRE 61 
levels over time through extensive culturing. MRE were defined as Enterobactericeae 62 
species that acquired non-susceptibility to ≥1 agent in ≥3 antimicrobial categories. In 63 
addition, due to the selective media used, the MRE had to be resistant to third-generation 64 
cephalosporins. MRE were detected in 60% of the patients, but their fecal levels varied 65 
considerably among patients and within the same patient (>6 and 4 orders of magnitude, 66 
respectively). Multivariate analysis of clinical metadata revealed an impact of intravenous 67 
beta-lactams (i.e. meropenem and piperacillin-tazobactam), which significantly 68 
diminished the fecal MRE levels in hospitalized patients. Consistent with a direct action of 69 
beta-lactams, we found an effect only when the patient was colonized with strains 70 
sensitive to the administered beta-lactam (p<0.001) but not with non-susceptible strains. 71 
We report previously unobserved inter and intra-individual heterogeneity in MRE fecal 72 
levels, suggesting that quantitative surveillance is more informative than qualitative 73 
surveillance of hospitalized patients. In addition, our study highlights the relevance of 74 
incorporating antibiotic treatment and susceptibility data of gut colonizing pathogens for 75 
future clinical studies and in clinical decision-making. 76 
 77 
INTRODUCTION 78 
Resistant Enterobacteriaceae, most notably those that are multidrug-resistant (MRE: 79 
acquired non-susceptibility to ≥1 agent in ≥3 antimicrobial categories) (1), are a major 80 
threat for hospitalized patients. Infections by Enterobacteriaceae such as Klebsiella 81 
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pneumoniae frequently begin by colonization of the intestinal tract (2), from where they 82 
can disseminate to the bloodstream and endanger patients’ lives (3). Intestinal 83 
colonization by multidrug resistant pathogens can promote their dissemination to other 84 
patients through fecal contamination of the environment (4). Understanding what 85 
influences MRE intestinal colonization is key to prevent MRE infections. 86 
The clinical variables associated with intestinal carriage of resistant 87 
Enterobacteriaceae in hospitalized patients have been analyzed before (5-10), but 88 
previous studies based on culture analysis defined carriage as the detectable presence of 89 
resistant bacteria in fecal samples irrespective of their levels: the question of how MRE 90 
levels varied within and between patients remained open. Intestinal levels, and not just 91 
detectable presence, are crucial for pathogen dissemination from the gut to the 92 
bloodstream (intra-dissemination) and dissemination between patients (inter-93 
dissemination) (11-13). Leukemia patients carrying higher levels (>106 colony forming 94 
units - CFUs/g of fecal sample) of resistant Enterobacteriaceae have 5-fold higher risk of 95 
developing bacteremia provoked by these Enterobacteriaceae (11). In addition, patients 96 
carrying higher relative abundance of Enterococcus or Klebsiella pneumoniae in feces, as 97 
determined through microbiota sequencing analysis, have increased risk of developing 98 
bloodstream infections by these organisms (12, 13). On the other hand, studies with 99 
vancomycin-resistant Enterococcus (VRE) showed that high intestinal pathogen loads 100 
(>104 CFUs/g) enhance contamination of a patient’s environment (4), which facilitates 101 
dissemination to other patients (14).  102 
While it is important to identify and understand the factors that impact intestinal 103 
levels of resistant pathogens, few clinical studies have sought to quantify pathogen loads. 104 
Two studies—performed in a single medical center—concluded that the 105 
administration of antibiotics with activity against anaerobic bacteria can increase the fecal 106 
density of VRE and Gram-negative resistant bacilli (4, 15). This effect may have been 107 
caused by depletion of anaerobic commensal microbes, thought to be important in 108 
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providing colonization resistance (16, 17). However, it is not clear if all antibiotics with 109 
antianaerobic activity will increase to the same extent MRE intestinal colonization levels. 110 
For example, antibiotics administered intravenously (IV) to treat bloodstream infections 111 
must be excreted through the bile in order to reach the intestinal tract. Thus, certain IV 112 
antianaerobic therapies may not reach high enough concentrations in the gut to promote 113 
MRE intestinal colonization. Besides, while certain antianaerobic therapies mainly affect 114 
anaerobes (i.e. metronidazole, clindamycin), others—such as beta-lactams—could impact 115 
the growth of MRE directly if they are excreted into the gut in sufficient amounts and that 116 
particular MRE is sensitive to the antibiotic. 117 
Here we conducted an extensive prospective study to examine the effect of specific 118 
antibiotics, as well as other factors such as antifungal treatments or neutropenia, on the 119 
gut expansion of MRE. We focused on acute leukemia patients, which are frequently 120 
colonized by resistant Enterobacteriaceae (11), to evaluate the range of colonization levels 121 
within and between patients, and to further elucidate the impact of IV-administered 122 
antibiotics and other clinical factors on the intestinal levels of MRE.  123 
RESULTS 124 
Study population 125 
We initiated a study of 133 acute leukemia patients (Supplementary Tables 1-2), which 126 
lasted 18 months. Patients were tracked over multiple hospitalizations (median 127 
hospitalizations per patient=3; median hospitalization length=26 days; median number of 128 
days a patient was followed=70). The most frequent causes of hospital admission were 129 
chemotherapy, infection and transplantation (Supplementary Tables 3,5).  130 
Acute leukemia patients received multiple antibiotic treatments during their 131 
hospitalization periods (Supplementary Tables 3, 4, 6). All antibiotics were IV-132 
administered except ciprofloxacin, which was administered orally. Ciprofloxacin, 133 
administered as prophylaxis immediately upon hospital admission for chemotherapy or 134 
transplantation, was the most frequently received antibiotic. Other frequently used 135 
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antibiotics administered for empiric treatment of suspected bacteremia included beta-136 
lactams, mainly piperacillin-tazobactam (PTZ) and meropenem, the aminoglycoside 137 
amikacin and the glycopeptide vancomycin. Similar results were obtained when days of 138 
therapy (DOT) per 1000 patient days were calculated (Supplementary Table 4). Here, 139 
ciprofloxacin was the therapy with the most DOT, followed by meropenem, PTZ, 140 
vancomycin and amikacin.  141 
MRE prevalence in fecal samples from acute leukemia patients 142 
A total of 802 fecal samples were collected from 133 patients during the study period (6 143 
samples on average per patient). MRE could be detected in 221 samples (27.6%) collected 144 
from 80 (60.1%) of the analyzed patients. In 67.8 % of the colonized patients, MREs could 145 
be isolated in one or more consecutive samples obtained during the same hospital 146 
admission period. The most frequently isolated MRE were Escherichia coli, Citrobacter 147 
freundii and K. pneumoniae (Figure 1A). Polymicrobial MRE colonization was relatively 148 
frequent: 20.4% of the MRE positive fecal samples were colonized by more than one MRE 149 
species (Figure 1B). In addition, MRE strains belonging to the same species but with 150 
different antibiotic resistance pattern were identified in 31.7 % of the MRE positive 151 
samples. A summary of the detected resistances is shown in Figure 1C and Supplementary 152 
Tables 7-8. As expected, considering the media used for MRE isolation, the majority of MRE 153 
isolates were resistant to penicillins and third generation cephalosporins (i.e. 100% 154 
resistant to ampicillin and 93.9% resistant to cefotaxime). Consistent with the use of 155 
ciprofloxacin as prophylactic agent, most MRE isolates were resistant to ciprofloxacin 156 
(86.6%). In addition, the majority of isolates were resistant to PTZ (82.3%) and 157 
approximately 50% of the isolates were resistant to carbapenems (i.e. imipenem and/or 158 
ertapenem). The proportion of resistance varied considerably among different species 159 
(Supplementary Table 7).  160 
MRE fecal levels differ significantly within and between patients 161 
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The levels of MRE (number of CFUs per gram of feces) varied significantly among different 162 
samples from the same patient (acquired at different days) and also between patients 163 
(Figure 2, Supplementary Table 9). Detected MRE reached high levels in some patients 164 
(1.43x108 CFUs/g) while in others it stayed scarcely within the limit of detection (50 165 
CFUs/g of feces). We saw no statistical significant differences in colonization levels among 166 
different MRE species (p=0.2; Figure 2B). In order to analyze the dynamics of MRE 167 
colonization levels, we studied the change in MRE levels in pairs of fecal samples. The total 168 
number of analyzed pairs was 135, obtained from 59 patients. The analysis showed that 169 
the levels of MRE changed over time (Figure 2C, D, Supplementary Figure 1) with a pattern 170 
suggesting that once an MRE had colonized the intestinal tract, its levels tended to 171 
decrease (Figure 2C, D, p=0.004). 172 
Antibiotic intravenous therapies that include beta-lactams PTZ and/or meropenem 173 
decrease MRE fecal levels. 174 
We next studied clinical factors that could explain the detected variability in MRE levels, 175 
focusing first on antibiotics. Based on previous studies, that have detected an effect of 176 
antianaerobic therapies on the intestinal levels of VRE and resistant gram-negative Bacilli,  177 
including MRE (4,15), we first asked whether the introduction of an antibiotic with activity 178 
against anaerobes between two consecutive samples acquired from the same patient 179 
changed the MRE levels (see in Supplementary Table 10 the antibiotic administered in 180 
each pair of samples). As previously described (15), we did not include in this analysis 181 
those pairs of samples that had received a therapy with antianaerobic antibiotics in the 182 
previous week. Interestingly, introduction of antibiotics with activity against anaerobes 183 
between two consecutive samples (21 pairs of samples from 18 patients) diminished on 184 
average significantly more the intestinal levels of MRE (Figure 3A, p=0.026), as compared 185 
to pairs of samples in which an antianaerobic treatment was not administered (38 pairs of 186 
samples from 21 patients).  187 
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In our hospital unit, the most frequently used antibiotics with activity against 188 
anaerobes were IV beta-lactams (mainly PTZ and meropenem), which can also directly 189 
inhibit the growth of some MRE strains. Indeed, in the 21 pairs of samples included in the 190 
group that received antianaerobic therapies, the patient had received at least one of these 191 
two beta-lactams (Figure 3B), suggesting a major role for these antibiotics in the detected 192 
reduction of MRE levels.   193 
Impact of IV beta-lactams (PTZ and meropenem) on MRE fecal levels depends on the 194 
MRE resistance profile 195 
The role of IV beta-lactams (i.e. PTZ and meropenem) in decreasing MRE levels 196 
could be indirect (e.g. through changes in the microbiome that promote MRE depletion) or 197 
it could be direct (by inhibiting MRE growth). To test if IV beta-lactam administration was 198 
directly reducing MRE levels, we analyzed the effect of these antibiotics, taking into 199 
account the resistance pattern of the MREs isolated (see in Figure 4 and Supplementary 200 
Table 11 the antibiotic administered in each pair of samples and the resistant pattern of 201 
the MREs isolated). Notably, beta-lactam administration did not affect MRE levels when the 202 
MREs isolated in a pair of samples were non-susceptible to the administered antibiotic 203 
(Figure 4A, p=0.77; 14 pairs of samples from 9 patients). In contrast, beta-lactam 204 
administration significantly diminished MRE fecal levels when all the strains isolated 205 
within a pair of samples were susceptible to the beta-lactam administered (Figure 4A; 206 
p=0.002; 16 pairs of samples from 15 patients). We carried out the same analysis but now 207 
excluding the patients who had received in the previous week another beta-lactam therapy 208 
and saw a similar effect: the levels of MRE strains susceptible to the antibiotic 209 
administered decreased (p=0.001), but we detected no change in non-susceptible strains 210 
(p=0.33) (not shown). Notably, this inhibitory effect of beta-lactams on susceptible MRE 211 
strains was not associated with treatment length (Supplementary Figure 2A).  212 
We noticed that the proportion of MRE species within each group of analyzed 213 
samples differed (Figure 4A; Supplementary Table 11). For example, C. freundii was 214 
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common in samples not receiving beta-lactams but was undetected in samples receiving 215 
beta-lactams that contained beta-lactam-susceptible strains from other species. To 216 
corroborate that the inhibition of susceptible strains was due to the beta-lactams 217 
administered and not to confounding differences in their composing MRE species, we re-218 
analyzed the samples exclusively colonized with E. coli MRE strains, the most abundant 219 
MRE species in our cohort. We saw a similar inhibitory effect of beta-lactams in samples 220 
exclusively colonized with E. coli (Supplementary Figure 3; p=0.035; 9 pairs of samples 221 
from 9 patients).  222 
The cultivation media used for MRE isolation selects for strains that are producers 223 
of extended-spectrum beta-lactamases (ESBL). We confirmed that most of the isolated 224 
strains pre and post beta-lactam administration were ESBL producers (80% of analyzed 225 
strains; Supplementary Table 11). Most importantly, a similar impact of beta-lactams on 226 
MRE levels was detected when we included in the analysis only those pairs of samples 227 
containing ESBL+ strains (Supplementary Figure 4).  228 
Consistent with the inhibitory effect of IV beta-lactams on MRE susceptible strains, 229 
MRE could not be detected after beta-lactam administration in 75% of the cases in which 230 
the patient was colonized with MRE strains susceptible to the administered beta-lactam 231 
(Table 1; N= 16 pairs of samples from 15 patients). In contrast, MRE colonization persisted 232 
in the majority of the cases in which the patient was not receiving a beta-lactam (only 233 
26.1% clearance in 46 pairs of samples analyzed from 27 patients) or when the patient 234 
was colonized with strains non-susceptible to the administered beta-lactam (28.5% 235 
clearance in 14 pairs of samples analyzed from 9 patients; Table 1).  236 
Interestingly, pairs of samples colonized with MRE susceptible strains that were 237 
not cleared after IV beta-lactam administration were associated with shorter antibiotic 238 
treatment, compared to those pairs of samples where the clearance was detected (p=0.11). 239 
(Supplementary Figure 2B).  240 
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A separate analysis of the two most frequently administered beta-lactams (i.e. 241 
meropenem and PTZ) provided similar results. As compared to pairs of samples in which a 242 
beta-lactam was not administered (46 pairs of samples from 27 patients), introduction of 243 
meropenem significantly reduced the MRE levels of strains sensitive to this antibiotic 244 
(p=0.005; Figure 4B; Table 1; 13 pairs of samples from 13 patients). PTZ also reduced the 245 
levels of MRE strains susceptible to this antibiotic (Figure 4C; p=0.03), although the 246 
number of pairs of samples available for this analysis was low (3 pairs of samples from 3 247 
patients). PTZ did not significantly modify the levels of MRE strains non-susceptible to this 248 
antibiotic (Figure 4C; p=0.3; 10 pairs of samples from 8 patients). Interestingly, the levels 249 
of non-susceptible strains increased, on average, with meropenem treatment (Figure 4B; 250 
p=0.017; 4 pairs of samples from 3 patients). Nevertheless, the number of pairs of samples 251 
available for this last analysis was low and the MRE expansion only occurred in 2 out of the 252 
4 analyzed cases (Figure 4B). A similar impact of individual beta-lactams on MRE 253 
dynamics was detected in those pairs of samples containing exclusively ESBL producing 254 
strains (Supplementary Figure 4). 255 
Other drugs showed no impact on MRE colonization 256 
Consistent with its poor biliary excretion, (18, 19) other frequently administered 257 
antibiotics such as aminoglycosides (i.e. amikacin) or glycopeptides (i.e. vancomycin and 258 
teicoplanin) did not induce observable changes in MRE levels (Supplementary Figure 5, 259 
p>0.05). We also saw no impact for amikacin on strains sensitive to this antibiotic 260 
(p=0.485, not shown). The effect of amikacin on non-susceptible strains was not evaluated 261 
due to the low number of pairs of samples available (N=1). The effect of quinolones on 262 
MRE dynamics could not be evaluated since they were administered immediately after 263 
hospital admission, before the first fecal sample could be collected.  264 
Administration of anti-fungals such as caspofungin or amphotericin did not impact 265 
MRE levels either (p>0.25). In addition, initiation of neutropenia (p=0.9), mucositis 266 
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(p=0.83) or starting parenteral feeding (p=0.79) did not affect MRE dynamics between 267 
pairs of consecutive samples. 268 
We next applied multivariate statistical analysis, taking into account all clinical 269 
variables previously analyzed and other possible confounding factors (i.e. gender, age, type 270 
of admission, leukemia type). This analysis confirmed IV-administered beta-lactams to be 271 
an independent variable associated with MRE reduction when the MRE is sensitive to the 272 
administered beta-lactam (p=0.001). 273 
Beta-lactams (i.e. meropenem/PTZ) could select for MRE clones resistant to the 274 
administered antibiotic 275 
The results obtained suggest that IV beta-lactam therapy (i.e. meropenem or PTZ) 276 
could diminish the intestinal loads of MRE sensitive to the administered beta-lactam. 277 
However, beta-lactam therapy has the implied risk of selecting for resistant strains that 278 
could occupy the niche left by the sensitive ones. To investigate this possibility, we focused 279 
on patients that were initially colonized with an MRE that was sensitive to the 280 
administered beta-lactam and asked whether their levels of MRE and their resistance 281 
patterns changed in time (Figure 5, Supplementary Figures 6 and 7). As previously 282 
described, meropenem diminished the intestinal loads of meropenem-sensitive strains. 283 
During meropenem administration, MRE levels decreased in 12 out of 14 analyzed cases 284 
and MRE levels were below the detection limit in 10 cases. Moreover, MRE could no longer 285 
be detected in any sample collected after clearance and during the treatment (8 samples 286 
from 4 patients that were collected in weeks following MRE elimination). Notably, in 1 out 287 
of 4 events in which we could detect MRE during the meropenem treatment, both sensitive 288 
and resistant strains to this antibiotic were detected, although the resistant strain was 289 
from a different species than the original susceptible strain. Introduction of PTZ decreased 290 
MRE levels in the 3 cases in which patients were colonized with strains susceptible to this 291 
antibiotic. However, strains non-susceptible to PTZ arose and expanded during PTZ 292 
treatment in 2 out of 3 analyzed cases. In this particular case, the non-susceptible strains 293 
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belong to the same species as the original susceptible ones. Thus, although administration 294 
of meropenem and PTZ can overall reduce the levels of MRE susceptible strains, 295 
occasionally, non-susceptible MRE strains may arise.    296 
Finally, we asked whether cessation of beta-lactam treatment would enable the 297 
expansion of MRE strains in those cases in which we observed MRE clearance during 298 
treatment.  We only had samples from two patients treated with meropenem for this type 299 
of analysis (Supplementary Figure 6). In one of these patients (i.e. 105), an MRE from a 300 
different species than the one eliminated during meropenem treatment was detected in 301 
fecal samples collected 21 days after meropenem cessation. Interestingly, in the patient 75, 302 
an MRE (from the same species and with the same antibiotic resistant pattern as the one 303 
eliminated during meropenem treatment) was detected 9 days after meropenem 304 
cessation, indicating that MRE re-expansion could occur after meropenem withdrawal.  305 
DISCUSSION 306 
We conducted an extensive survey on MRE intestinal colonization levels in patients 307 
hospitalized to receive cancer treatments, including the effect of a range of clinical factors 308 
on MRE dynamics. This is, to our knowledge, the first study to investigate quantitatively, 309 
through extensive culturing, MRE colonization in such a large cohort of patients, allowing 310 
us to investigate the factors associated with temporal changes of MRE levels in the 311 
intestinal tract of the same patient. The extensive data generated in this study is publically 312 
available (see supplementary material) so that the scientific and clinical community can 313 
potentially investigate other factors influencing MRE dynamics within hospitalized 314 
patients besides the effect of beta-lactams that we revealed here.  315 
 Our analysis showed that MRE levels varied significantly between patients and 316 
between samples collected from the same patient during the same hospital admission 317 
period. Therefore, based on these results and previous studies indicating that higher levels 318 
of resistant bacteria increased the risk of pathogen dissemination to the bloodstream or to 319 
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the environment (4, 11), it may be useful for clinical practice to accurately measure fecal 320 
MRE levels, beyond determining the presence or absence of fecal carriage. 321 
When we started our investigation we expected to find confirmation that 322 
antibiotics with antianaerobic activity promote higher intestinal colonization levels of 323 
multidrug resistant pathogens such as VRE or resistant gram-negative bacilli (4, 15). 324 
However, we found instead that the antibiotics with antianaerobic activity used in our 325 
hospital unit diminished, and not increased, the fecal levels of MRE. A separate analysis of 326 
specific antibiotics revealed that the beta-lactams (PTZ and meropenem) had the greatest 327 
effect. Beta-lactams, although administered intravenously, are partially excreted through 328 
the bile to the intestinal tract (18), and could directly affect the growth of MRE. Indeed, we 329 
were able to demonstrate that IV administration of PTZ and meropenem diminished the 330 
levels of MRE when the strain was sensitive, and not when it was resistant to the 331 
administered antibiotic, pointing to the direct effect of these antimicrobials. In some cases, 332 
the impact of these beta-lactams was substantial, clearing MRE from the intestinal tract in 333 
patients previously colonized with more than 106 CFU/g of feces. This result agrees with 334 
previous observations in two patients that were highly colonized with Enterobacteriaceae 335 
strains sensitive to meropenem, and that were undetectable after IV meropenem 336 
treatment (15). Notably, for a couple of patients, in which MRE had been cleared during 337 
meropenem treatment, fecal samples could be analyzed after meropenem cessation. In 338 
these two patients MRE could be detected again after meropenem withdrawal, suggesting 339 
that the inhibitory effect of meropenem was only effective during its administration. 340 
Additional studies should be performed in order to evaluate this in a higher number of 341 
patients. Since meropenem withdrawal usually occurred at the end of the hospitalization 342 
period, this type of analysis would require the collection and analysis of samples beyond 343 
the hospitalization period, which was not performed in this study.    344 
The effectiveness of PTZ therapy against certain MRE strains (i.e. those producing 345 
ESBL) differs significantly depending on the study. Thus its utility to treat infections by 346 
 o
n
 D
ecem
ber 12, 2019 at INRA - Institut National de la Recherche Agronom
ique
http://aac.asm
.org/
D
ow
nloaded from
 
Ve
rs
io
n 
po
st
pr
in
t
Comment citer ce document :
Djukovic, A., González-Barberá, E. M., Sanz, J., Artacho, Peñaranda, Herrera, Garzón, Salavert,
López-Hontangas, Xavier, K. B., Kuster, B., Debrauwer, L., Rolain, J.-M., Sanz, M., Xavier,
J., Ubeda, C. (Auteur de correspondance) (2020). High heterogeneity of multidrug-resistant
Enterobacteriaceae fecal levels in hospitalized patients is partially driven by intravenous
beta-lactams. Antimicrobial Agents and Chemotherapy, 64 (2), 33 p. , DOI : 10.1128/AAC.01415-19
 
14 
these pathogens remains controversial (20). Indeed, in the only randomized clinical trial 347 
performed, PTZ was shown to be less effective than meropenem in the treatment of 348 
bloodstream infections produced by Enterobacteriaceae ESBL producer strains (21). 349 
Reasons that explain different PTZ treatment outcomes include the site of infection and 350 
susceptibility of the ESBL producing strain to PTZ. Our results are consistent with these 351 
differential effects of PTZ on ESBL producing strains. We found that PTZ decreased the 352 
fecal levels of ESBL producing Enterobacteriaceae that are susceptible to the treatment, 353 
while it did not affect the levels of those non-susceptible to this antibiotic. Nevertheless, 354 
the obtained results should be confirmed in an extended study since only a few pairs of 355 
samples could be included in this analysis. Our data also show occasional selection for 356 
strains resistant to PTZ (2 out of 3 cases) and meropenem (1 out of 14 cases). Thus, 357 
although both IV PTZ and meropenem decrease the intestinal levels of susceptible strains, 358 
their usage should be restricted to the treatment of suspected cases of infection, rather 359 
than decontamination of MRE susceptible strains from the intestinal tract. 360 
The administration of beta-lactams and more specifically PTZ, apparently did not 361 
promote large expansion of MRE strains non-susceptible to the administered beta-lactam 362 
in acute leukemia patients. However, our analysis did suggest that the levels of MRE strains 363 
non-susceptible to meropenem might increase after meropenem administration. This 364 
result, despite passing the common threshold of statistical significance, was based on only 365 
four pairs of samples and a closer inspection shows that MRE expanded in only half of 366 
those cases. Thus, additional studies should be performed to validate this result. 367 
Nevertheless, this is consistent with the result obtained in a study in which carbapenem 368 
administration was associated with a higher relative abundance of carbapenem-resistant 369 
K. pneumoniae, measured by 16s rRNA sequencing, which was associated with increased 370 
risk of bloodstream infections (13). Thus, IV meropenem can reduce the fecal levels of 371 
susceptible strains, while it may promote the growth of resistant ones.  372 
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It is worth to mention that our hospital unit rarely uses clindamycin and 373 
metronidazole, two antibiotics with a major effect against anaerobic bacteria but with no 374 
direct effect against MRE. These antibiotics, in addition to PTZ, were some of the most 375 
frequently administered in a previous study showing higher levels of resistant gram-376 
negative bacilli during antianaerobic treatment (15). The different therapies administered 377 
in both studies may explain the different results obtained regarding the effect of 378 
antianaerobic antibiotics on the growth of resistant pathogens. Indeed, studies performed 379 
in mice have shown that parenteral administration of clindamycin consistently promoted 380 
high levels of MRE intestinal colonization. In contrast, intestinal density of MRE upon PTZ 381 
administration varied depending on the dose of the antibiotic administered, the pathogen 382 
inoculum concentration and its level of antibiotic resistance (22). Future studies should 383 
elucidate how these variables influence the capacity of beta-lactams to promote intestinal 384 
colonization by MRE in patients.  385 
We acknowledge several limitations of our study. First, our study was performed in a very 386 
specific human population (acute leukemia patients) that may already display an altered 387 
microbiota due to prior treatments. Nevertheless, we would expect that beta-lactams effect 388 
on susceptible MRE strains would be the same in other types of hospitalized patients since 389 
this effect is direct and probably not dependent on the microbiota. Moreover, acute 390 
leukemia patients are one of the cohorts with higher risk of infection due to intestinal 391 
colonization by MRE and could therefore benefit the most from this type of studies. 392 
Second, our study was restricted to the subset of MRE that were able to grow on plates 393 
containing a 3rd generation cephalosporin, designed for the detection of ESBL producing 394 
strains. Indeed, most of the analyzed strains were ESBL producers. In addition, most of the 395 
isolated strains were resistant to quinolones probably because ciprofloxacin is 396 
administered in our hospital unit as prophylaxis immediately upon patient’s hospital 397 
admission. Additional work should be carried out in order to validate our findings on 398 
strains with a different resistant background. In addition, further work should be 399 
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performed in order to study if the effect of beta-lactams on MRE levels will depend on the 400 
different mechanisms of cephalosporin or carbapenem resistance, which were not studied 401 
here. Third, our results did not allow us to evaluate the impact of clinical factors on low 402 
abundant MRE populations since the MRE antibiotic resistant pattern and taxonomy was 403 
only characterized in a few representative isolates from each sample. Fourth, we were able 404 
to validate the inhibitory effect of specific beta-lactams on a particular individual MRE 405 
species (i.e. E. coli). However, the effect on other individual MRE species of interest (e.g. K. 406 
pneumoniae) could not be evaluated due the limited number of samples containing 407 
exclusively these other MREs. Additional studies should be performed to confirm the effect 408 
of beta-lactams on other MRE species of interest. Finally, we were not able to evaluate the 409 
effect of MRE levels on the risk of bacteremia due to the low number of samples available 410 
for this analysis (i.e. N=6 fecal samples collected before bacteremia detection containing 411 
the same MRE species as the one isolated in the bloodstream). Nonetheless, previous 412 
studies have already pointed to a link between high intestinal levels of drug-resistant 413 
bacteria and increased risk of bloodstream infections provoked by these bacteria (11, 13). 414 
Additional work should be performed to corroborate those results using quantitative 415 
measurements to evaluate if a particular threshold leads to higher risk of bloodstream 416 
infections.  417 
In summary, our results revealed a wide diversity of intestinal MRE levels and 418 
highlighted the relevance of quantitatively analyzing these levels in surveillance and/or 419 
clinical studies. Certain IV-administered antibiotics had a direct effect on the intestinal 420 
growth of MRE, and this effect depended on the sensitivity of the pathogen to the given 421 
antibiotic. Overall, our study highlights the relevance of incorporating antibiotic treatment 422 
and susceptibility data of gut colonizing pathogens for future clinical studies and in clinical 423 
decision-making. 424 
MATERIALS AND METHODS 425 
Ethics 426 
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This study was approved by the Ethics Committee of CEIC Dirección General de Salud 427 
Pública and Centro Superior de Investigación en Salud Pública (20130515/08). All 428 
included patients gave their consent to participate in the study. 429 
Sample and metadata collection 430 
Fecal samples were collected weekly from November of 2013 until April of 2015 from all 431 
acute leukemia patients hospitalized at the Hospital La Fe (Valencia, Spain) who agreed to 432 
participate in this study. Procedures of sample collection and metadata acquisition are 433 
described in detail in the supplementary data.  434 
Assessing MRE colonization levels and characterization of MRE isolates. 435 
MRE levels, defined as the number of MRE CFUs detected per gram of feces, were 436 
determined by culturing 10-fold dilutions of fecal samples in Brilliance ESBL agar plates 437 
(Oxoid), which contain cefpodoxime, a third generation cephalosporin as selective agent. 438 
These plates allow for isolation of Extended Spectrum Beta-Lactamase (ESBL) producing 439 
organisms, while inhibiting the growth of non-ESBL Enterobacteriaceae and most AmpC 440 
organisms, allowing mainly for identification of ESBL-producing E. coli and the Klebsiella, 441 
Enterobacter, Serratia and Citrobacter group (known as KESC). The number of colonies in 442 
each plate was normalized by dilution and fecal weight in order to calculate the levels of 443 
colonization of MRE per gram of feces. To confirm that the detected colonies were MRE, 444 
the taxonomy and resistance pattern of 5 isolated colonies per sample were determined 445 
through the Maldi-TOF and VITEK system (supplementary methods). In addition, 446 
production of extended spectrum beta-lactamases was analyzed in a subset (11%) of the 447 
characterized MRE isolates (Supplementary Table 11, Figure 4) as described in the 448 
supplementary methods.  449 
Defining pairs of samples and calculating the fold change (FC) among pairs of 450 
samples to study MRE dynamics. 451 
For analyzing the dynamics of MRE colonization levels, we calculated the log2FC in MRE 452 
levels in pairs of fecal samples. The pairs were defined as two samples consecutively 453 
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collected from the same patient and same hospital admission period. The first sample of 454 
the pair was always positive for MRE. Taking into account the weekly sampling strategy 455 
performed in this study, in most cases the two samples were collected one week apart 456 
from each other.  457 
Sometimes, MRE could not be detected in the second sample of a pair of samples; we 458 
define those cases as MRE clearance. To avoid infinite values that would arise by dividing 459 
by 0, the limit of the detection (i.e. 50 CFUs/g) was added to the values obtained in each 460 
sample as pseudo-counts before calculating the FC.  461 
The MRE clearance rate was defined as the number of pairs of samples from the total 462 
analyzed in which MRE could not be detected in the second sample of the pair. 463 
Description of the comparisons performed to evaluate the effect of clinical factors 464 
on MRE dynamics.  465 
1. Effect of antianaerobic antibiotics on MRE dynamics.  466 
The log2FC obtained from pairs of samples in which a therapy with an antianaerobic 467 
antibiotic had been initiated was compared with the log2FC of the group of pairs of 468 
samples that had not received such therapy. The group of pairs of samples that had 469 
received an antianaerobic therapy was defined, based on previous studies (4, 15), as those 470 
in which the MRE levels from the first sample of the pair were available within two weeks 471 
before the initiation of the regimen, no antianaerobic antibiotic had been administered 472 
within seven days before the regimen was initiated, the level of the second sample within 473 
the pair was determined at least two days after the initiation of the treatment but no more 474 
than seven days after the completion of the antibiotic course. Although we decided to 475 
follow this previously established criteria dictating that the second sample in a pair 476 
shouldn’t have been collected more than seven days after the cessation of the treatment, it 477 
is worth mentioning that in our study all the second samples of analyzed pairs were 478 
collected while the treatment was still ongoing. The length of the treatment was not 479 
accounted as a variable for this type of analysis. The MRE log2FC detected in this group of 480 
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samples was compared with the MRE log2FC obtained in pairs of samples in which no 481 
antibiotic with antianaerobic activity was received neither between the two samples of a 482 
pair (including the days in which the samples were collected) nor in the week before the 483 
date of collection of the first sample of the pair.  484 
Antibiotics included in the analysis with activity against intestinal anaerobes were: PTZ, 485 
amoxillin clavulanic, ampicillin, meropenem, ertapenem, imipenem, linezolid, 486 
metronidazole, tigecycline. Antibiotics included in the analysis that were considered not 487 
active against intestinal anaerobes were: gentamicin, amikacin, cloxacillin, aztreonam, 488 
cotrimoxazole, colistin, ciprofloxacin, levofloxacin, daptomycin, vancomycin, teicoplanin 489 
(23-30).  490 
Daptomycin, despite its in vitro effect against gram-positive anaerobic bacteria (27), was 491 
included within the group of antibiotics with no activity against intestinal anaerobes. We 492 
made this choice because in mice the parenteral administration of this antibiotic does not 493 
disrupt the anaerobic flora and does not promote the intestinal colonization of Extended-494 
Spectrum--Lactamase-producing K. pneumoniae (31). In addition, glycopeptides such as 495 
vancomycin and teicoplain were included in the group with no effect against intestinal 496 
anaerobes because they were administered intravenously and their biliary excretion is low 497 
(18, 19). Nevertheless, similar results as those shown in Figure 3 were obtained if 498 
glycopeptides were included within the group of antibiotics with activity against anaerobic 499 
bacteria (not shown). 500 
Patients did not receive antibiotic prophylaxis while outpatient. Moreover, in case the patient 501 
required an antibiotic for other indications (fever or other symptoms), the patient would be 502 
first hospitalized. For this reason, we did not account for the impact of outpatient antibiotic 503 
exposure on MRE levels and we focus our analysis on those antibiotics received during the 504 
hospitalization period. 505 
2. Effect of beta-lactam therapy and other clinical variables on MRE dynamics. 506 
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A comparison was performed between the log2FC obtained from pairs of samples in which 507 
a therapy with a beta-lactam antibiotic had been initiated and the group of pairs of 508 
samples that had not received such therapy. The group of pairs of samples that had 509 
received the beta-lactam therapy was defined as those in which the MRE levels from the 510 
first sample of the pair were available within two weeks before the initiation of the 511 
regimen, the levels of the second sample within the pair were determined at least two days 512 
after the initiation of the treatment but no more than seven days after the completion of 513 
the antibiotic course. As described above, although we decided to follow the criteria 514 
established by previous studies (4, 15), in our study, all the second samples of analyzed 515 
pairs were collected while the beta-lactam treatment was still ongoing. The length of 516 
antibiotic treatment was not accounted as a variable for this type of analysis. To study if 517 
the effect of beta-lactams on MRE change was direct (i.e. direct inhibition of MRE on 518 
susceptible strains), the pairs of samples selected were divided into two subgroups: (i) 519 
pairs of samples containing exclusively strains susceptible to the beta-lactam 520 
administered; (ii) pairs of samples containing exclusively strains non-susceptible to the 521 
beta-lactam administered. The MRE log2FC detected in these two groups of pairs of 522 
samples was compared with the MRE log2FC obtained in pairs of samples in which no beta-523 
lactam was received between the two samples of a pair (including the days in which the 524 
samples were collected). 525 
In addition to this type of analysis (Figure 4), we performed the same analysis but 526 
excluding from the beta-lactam group those pairs of samples that had received another 527 
beta-lactam in the week before the initiation of the beta-lactam therapy and we compared 528 
it with the groups of samples that had not received beta-lactams neither between the 529 
samples of a  pair (including the days in which the samples were collected) nor in the week 530 
before the date of collection of the first sample of the pair. This type of analysis led to 531 
similar results as indicated in the result section, although the number of samples included 532 
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in this analysis was lower. For this reason and to avoid redundancy, only the first type of 533 
analysis is shown in the Figure 4.  534 
The same comparisons as with beta-lactams were performed to assess the effect on MRE 535 
dynamics of other antibiotics (i.e. glycopeptides and aminoglycosides), antifungal 536 
treatments and initiation of parenteral feeding, mucositis or neutropenia. In the case of 537 
neutropenia, mucositis or parenteral feeding, the log2FC of pairs of samples in which these 538 
events were initiated was compared with pairs of samples collected during periods in 539 
which the patient did not have neutropenia, was not fed through the parenteral route or 540 
did not  develop mucositis.  541 
Besides the analysis described above on the effect of antibiotics on MRE changes, previous 542 
studies have also compared the levels of resistant pathogens identified during the 543 
administration of different groups of antibiotics. Nonetheless, that approach had 544 
limitations: (i) it did not take into account those samples in which the pathogen 545 
was unable to colonize because of the presence of the antibiotic, and (ii) it did not consider 546 
those samples in which the pathogen was eliminated upon the introduction of the 547 
antibiotic. As seen in this study, some of the most frequently administered antibiotics in 548 
our hospital unit (i.e. meropenem and PTZ) often do eliminate MRE when the strain is 549 
sensitive to the antibiotic administered. For this reason, and to make our study 550 
more comprehensive, we focused our analysis on the changes in MRE after the 551 
introduction of specific antibiotics, which allowed us to account for cases in which the 552 
effect of the antibiotic was the complete elimination of the pathogen. 553 
Statistical analysis.  554 
In the case of this descriptive study without hypothesis to be tested, the comparisons and 555 
p-values calculated were descriptive and exploratory. 556 
Two-tailed Student’s t-test was applied in order to analyze if the log2 Fold Change MRE 557 
levels between groups of samples were significantly different. Fischer’s exact test was 558 
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applied to define if MRE clearance rate (Table 1) was significantly different among groups 559 
of samples.  560 
Multivariate Lasso regression analysis was performed as described in supplementary 561 
methods.  562 
P values < 0.05 were considered statistically significant. 563 
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 701 
FIGURE LEGENDS 702 
Figure 1. MRE positive samples show diverse compositions and antibiotic resistance 703 
patterns of detected MRE isolates.  MRE could be detected in 221 samples collected from 704 
80 of the analyzed patients. (A) The most frequently isolated MRE belonged to the species 705 
Escherichia coli. Other detected MRE in order of prevalence were Citrobacter freundii, 706 
Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Morganella morganii, 707 
Citrobacter amalonaticus, Raoultella spp. and Escherichia hermanii. Other MRE species, 708 
including Citrobacter braakii, Proteus vulgaris, Serratia marscescens, Enterobacter 709 
aerogenes and Escherichia fergusonii were detected in only one sample. (B) In 45 of the 710 
221 MRE positive samples (20.4%), MRE belonging to more than one bacterial species 711 
could be identified, and in 70 of the MRE positive samples (31.7%), MRE strains belonging 712 
to the same species but with different antibiotic resistance pattern were identified. (C) 713 
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26 
Antibiotic resistance pattern of MRE isolates detected in 221 positive samples. When two 714 
isolates from the same sample have exactly the same resistance pattern and taxonomy, 715 
only one of the two isolates is shown. Columns and rows are grouped based on MRE 716 
taxonomy and antibiotics’ class. S: susceptible; I: intermediate resistant phenotype; R: 717 
resistant. NA: not-analyzed. 718 
 719 
Figure 2. MRE fecal levels differ significantly between patients but also within a 720 
patient. (A) MRE levels identified in all colonized fecal samples included in the study 721 
(N=221 samples) or the mean (obtained from log10 CFU data) of the MRE levels identified 722 
in colonized samples from each patient (N=80 patients). Whiskers represent minimum and 723 
maximum values. Horizontal lines represent the median and 25-75 percentiles. (B) MRE 724 
levels in fecal samples colonized exclusively with the indicated species (low abundant 725 
species: N≤5, are not included). No significant (ns) differences in MRE levels were 726 
detected between different species (Kruskal-Wallis test). N= 45 (C. freundii); 14 (E. 727 
cloacae); 13 (K. oxytoca); 65 (E. coli) and 31 (K. pneumoniae) samples.  (C) Changes in MRE 728 
levels among 135 pairs of consecutive fecal samples (see Methods for definition) collected 729 
from 59 patients. The grey bar represents the median of MRE levels. **p<0.01; Two-tailed 730 
paired Wilcoxon test. (D) Number of the total pairs of consecutive samples included in the 731 
study (all) and number of pairs of samples in which an increase in MRE levels (> 1 log2 fold 732 
change – FC; N=39) or a decrease in MRE levels (< -1 log2 FC; N=81) was detected.  733 
 734 
Figure 3. Antibiotic therapies including the beta-lactams piperacillin-tazobactam 735 
and meropenem decrease MRE fecal levels. (A) MRE log2FC among pairs of consecutive 736 
samples between  which a therapy with an antibiotic with activity against anaerobic 737 
bacteria was initiated (+), as compared to pairs of samples in which no antianaerobic 738 
antibiotics were administered (-). N=38 pairs of samples from 21 patients and 21 pairs of 739 
samples from 18 patients for the antianaero (-) and (+) groups respectively. *p<0.05; Two-740 
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27 
tailed t-test. Bars represents the mean, whiskers represent the SEM. (B) Antibiotics with 741 
antianaerobic activity that were administered between each pair of samples shown in (A). 742 
Colors in (A) indicate the taxonomy of the MRE identified in each pair of samples. Detailed 743 
taxonomy and antibiotic resistant pattern of all the MREs identified within each pair of 744 
samples is shown in Supplementary Table 10. PTZ=piperacillin-tazobactam.  745 
Figure 4. Impact of IV beta-lactams (piperacillin-tazobactam and meropenem) on 746 
MRE fecal levels depends on the MRE resistance profile. (A) MRE log2FC among pairs 747 
of consecutive samples between which a beta-lactam (i.e. piperacillin-tazobactam or 748 
meropenem) was administered (+) or not (-). MRE strains detected in the consecutive 749 
pairs of samples analyzed were either susceptible (S), or non-susceptible (R/I) towards 750 
the administered beta-lactam.  (B, C) Same as in (A) but only including pairs of samples in 751 
which the beta-lactam therapy initiated between the pair of samples was exclusively 752 
meropenem (B) or exclusively piperacillin-tazobactam (C). *P<0.05; **P<0.01; two-tailed t-753 
test compared with the group not receiving beta-lactams. The results show that beta-754 
lactams (i.e. meropenem and piperacillin-tazobactam) reduce the levels of MRE strains 755 
susceptible to the beta-lactam administered.  Colors indicate the taxonomy of the MRE 756 
identified in each pair of samples. Detailed taxonomy and antibiotic resistant pattern of all 757 
the MREs identified within each pair of samples is shown in Supplementary Table 11. The 758 
number of pairs of samples (S) and patients (P) included in each group are: no beta-lactam 759 
(S=46, P=27); susceptible to beta-lactams (S=16, P=15); non-susceptible to beta-lactams 760 
(S=14, P=9); susceptible to meropenem (S=13, P=13); non-susceptible to meropenem 761 
(S=4, P=3); susceptible to PTZ (S=3, P=3); non-susceptible to PTZ (S=10, P=8). 762 
Figure 5.  Meropenem and piperacillin-tazobactam decrease fecal levels of 763 
susceptible MRE but occasionally resistant strains emerge. MRE levels and sensitivity 764 
pattern to the beta-lactam received before and during therapy with meropenem (A) or 765 
piperacillin-tazobactam (PTZ) (B). Consecutive samples collected from the same patient 766 
and admission period are connected with a line. Sensitivity to the antibiotic is indicated 767 
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28 
when the MRE could be detected. Nº of samples in which an MRE could not be detected on 768 
each specific day is indicated. Note that the first sample contains always MRE strains 769 
susceptible to the beta-lactam received. S= susceptible, R= resistant, I=intermediate 770 
phenotype. Colors indicate the taxonomy of the MRE identified in each sample. Days are 771 
relative to the date of the first sample included in the figure for each patient. Graphs for 772 
each individual patient and samples collected after beta-lactam cessation are shown in 773 
Supplementary Figures 6 and 7. N= 14 patients for meropenem group and 3 patients for 774 
the PTZ group. Note that as compared to Figure 4, there is one more patient receiving 775 
meropenem in this Figure. This is because in Figure 4 a pair of samples was included in the 776 
group of pairs sensitive to meropenem only if all MRE strains characterized in the pair 777 
were sensitive to the antibiotic.  778 
 779 
Table 1. MRE clearance after beta-lactam (piperacillin-tazobactam or 780 
meropenem) administration.  781 
 782 
-lactama Susceptibilityb MRE clearance ratec   Significanced 
None NA 12/46 (26.1%)  
PTZ/Meropenem S 12/16 (75%) *** 
PTZ/Meropenem R/I 4/14 (28.5%) NS 
PTZ S 2/3 (66.6%) NS 
PTZ R/I 4/10 (40%) NS 
Meropenem S 10/13 (77%) * 
Meropenem R/I 0/4 (0%) NS 
 783 
a -lactam that was administered between a pair of samples. PTZ/Meropenem: 784 
piperacillin/tazobactam and/or meropenem were administered. Exclusively 785 
piperacillin/tazobactam (PTZ) or meropenem therapy was initiated between a pair of samples.  786 
b Susceptibility of the MRE to the administered antibiotic. S= susceptible; R/I=non-susceptible 787 
(resistant/intermediate phenotype). NA: non-applicable. 788 
c Number of pairs of samples from the total analyzed in which the MRE was not detected in the 789 
second sample of the pair. Numbers in parenthesis indicate % of clearance. 790 
d Significance. *P<0.05; ***P<0.001; NS=P>0.05; Fischer test comparing with the group in which no 791 
-lactams were administered. 792 
 793 
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